Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 18/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153631 | 1.00 | SYK (0.51) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL12998885 | 0.80 | SYK (0.52) | SYKCYP2C9HPGD | |
| SCHEMBL10425208 | 0.78 | SYK (0.51) | SYKCYP2C9HPGD | |
| SCHEMBL6153358 | 0.77 | SYK (0.48) | SYKKCNH2 | |
| SCHEMBL6153359 | 0.77 | SYK (0.48) | SYKKCNH2 | |
| SCHEMBL1077404 | 0.76 | SYK (0.50) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL5605298 | 0.76 | SYK (0.50) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL4437198 | 0.76 | SYK (0.50) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL5613415 | 0.76 | SYK (0.50) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14956519 | 0.76 | LRRK2 (0.71) | SYKMAPK3MAPK1KCNH2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | SYK 1613/4885MAPK3 133/4885MAPK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.